Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

The present invention discloses compounds according to Formula I:

##STR00001##

wherein R.sup.1, R.sup.2a, X, Y, and Z are as defined herein.

The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

The present invention discloses compounds according to Formula I:

##STR00001##

wherein R.sup.1, R.sup.2a, X, Y, and Z are as defined herein.

The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Provided is a new application of a chemokine receptor CCR6 inhibitor in preventing the recurrence of psoriasis. Specifically, provided is a use of the chemokine receptor CCR6 inhibitor for preparing a preparation or composition that is administered to a subject so as to prevent the recurrence of psoriasis in the subject. Also provided is a pharmaceutical product that prevents the recurrence of psoriasis. Using the provided drug products may effectively prevent or alleviate the recurrence of psoriasis.

Provided is a new application of a chemokine receptor CCR6 inhibitor in preventing the recurrence of psoriasis. Specifically, provided is a use of the chemokine receptor CCR6 inhibitor for preparing a preparation or composition that is administered to a subject so as to prevent the recurrence of psoriasis in the subject. Also provided is a pharmaceutical product that prevents the recurrence of psoriasis. Using the provided drug products may effectively prevent or alleviate the recurrence of psoriasis.

The present disclosure is related to methods of treating autoimmune disorders in a subject comprising administering immunoglobulin-like transcript 7 (ILT7) binding proteins to a subject having elevated type I interferon gene signature (IFNGS). The present disclosure also relates to methods of reducing pDCs in tissues comprising administering an ILT7-binding protein to a subject in need thereof.

A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R.sup.1, W, V, and R.sup.3 are as defined in claim 1. ##STR00001##

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.